Dihexa

Origin and Structure

Dihexa is a small oligopeptide with the formal name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It was developed in the laboratory of Joseph Harding at Washington State University in the early 2010s as part of a medicinal-chemistry program aimed at stripping the angiotensin IV sequence down to a metabolically stable, brain-penetrant core that retained the parent molecule's procognitive activity. The two hexanoic acid caps were added specifically to defeat aminopeptidase cleavage and increase lipophilicity enough to cross the blood-brain barrier after oral administration in rodents.

The compound is often described in the nootropic community as a "peptidomimetic" rather than a true peptide because only a single peptide bond separates the two modified amino acid residues. That distinction matters: unlike most peptides on this library, dihexa was designed from the start for oral dosing.

Mechanism of Action

Dihexa's primary activity is allosteric potentiation of the hepatocyte growth factor (HGF) / c-Met system. It does not activate c-Met directly; instead, it binds HGF and increases its affinity for the c-Met receptor tyrosine kinase, amplifying endogenous signaling rather than imposing a constitutive signal. This is mechanistically unusual among cognitive peptides and is the feature most frequently highlighted in the published literature.

Downstream of c-Met activation, the PI3K/Akt and MAPK/ERK cascades drive dendritic spine formation, synaptogenesis, and neuronal survival. In aged rats treated with dihexa, Harding's group reported measurable increases in hippocampal dendritic spine density and synaptophysin expression alongside performance gains on the radial-arm water maze — effects the authors attributed to rebuilding of lost synaptic connectivity rather than transient neurotransmitter modulation.

Preclinical Evidence

The published dihexa literature is concentrated in a small number of Harding-lab and collaborator papers, supplemented by independent work using dihexa as a tool compound to probe HGF/c-Met signaling. Themes include:

• Aged-rat cognition. Reversal of scopolamine-induced and age-related deficits in spatial learning at doses reported as many orders of magnitude more potent than the angiotensin IV parent.
• Parkinsonian models. Neuroprotection of dopaminergic neurons in 6-OHDA and MPTP models, consistent with the trophic signature of HGF.
• Synaptogenesis in vitro. Dose-dependent dendritic spine formation in hippocampal slice cultures at low-nanomolar concentrations.

Human Clinical Data

There are no completed human clinical trials of dihexa as of 2026. The compound has never advanced to an IND-supported program and is not FDA-approved for any indication. All claims about cognitive enhancement in humans are anecdotal and drawn from self-report in the nootropic community — a thin evidence base given the compound's molecular potency and the fact that c-Met is a proto-oncogene whose sustained activation is implicated in several cancers.

Safety Considerations

The c-Met pathway is the central concern with dihexa. HGF/c-Met signaling is dysregulated in numerous solid tumors, and c-Met inhibitors — not potentiators — are the direction of oncology drug development. Chronic potentiation of this pathway in humans has no long-term safety data. Nothing in the published rodent work rules out a pro-tumorigenic effect with extended use, and several cancer biologists have flagged this as a reason for caution.

Acute tolerability reports are generally benign — mild headache and occasional GI effects — but these are not trial-grade data.

Practical Considerations

Community protocols typically cite 8–45 mg per day orally, often cycled in 4–8 week blocks, but these figures are extrapolated from rodent dosing with generous assumptions about interspecies scaling. Dihexa is sold only through research-chemical suppliers; it is not available from compounding pharmacies. Analytical quality varies substantially. For readers interested in better-characterized cognitive peptides with real clinical exposure, our Semax reference page and Cerebrolysin overview cover compounds with decades of in-human use in Russia and Central Europe.

The Bottom Line

Dihexa is a mechanistically elegant compound with striking rodent data and essentially no human evidence base. The HGF/c-Met potentiation story is real and interesting; the oncology implications of chronically amplifying that signal in humans are unresolved. For now it remains a research compound — not a therapy — and anyone using it outside a formal trial is doing so on the basis of preclinical extrapolation alone.